Anlon Healthcare Limited IPO
Anlon Healthcare is a chemical manufacturing company engaged in producing:
a) High Purity Pharmaceutical Intermediates – raw materials and key starting materials used in the manufacturing of Active Pharmaceutical Ingredients (APIs).
b) Active Pharmaceutical Ingredients (APIs) – core raw materials used in pharmaceutical formulations like tablets, capsules, syrups, ointments, as well as nutraceuticals, personal care, and veterinary products.
The company is among the few manufacturers of Loxoprofen Sodium Dihydrate in India, an important API used in the treatment of various pain and inflammation-related conditions.
Product Portfolio
a) Anlon Healthcare’s diversified portfolio includes Pharma Intermediates, APIs, Nutraceutical APIs, Personal Care Ingredients and Veterinary APIs. Products comply with leading pharmacopeia standards such as IP, BP, EP, JP, and USP.
b) Current Product Development Status: 65 commercialized products, 28 products at pilot stage and 49 products under laboratory testing
Custom Manufacturing & R&D
The company also undertakes custom manufacturing services for complex or novel compounds, ensuring higher-than-standard purity levels.
i) Expertise in reducing impurities and optimizing processes.
ii) Active involvement in Drug Master File (DMF) preparation and filings across global markets.
iii) Regulatory approvals already secured from Brazil (ANVISA), China (NMPA), and Japan (PMDA), with filings in multiple other geographies including the EU, Russia, USA, and Spain.
Global Presence
Anlon Healthcare serves both domestic and international markets. Its products are supplied to over 15 countries, including Italy, Germany, South Korea, China, Argentina, Chile, Colombia, Mexico, Egypt, Turkey, Japan, Brazil, UK, and UAE.
Key Strengths
i) Strong product portfolio with presence in multiple therapeutic and application segments.
ii) One of the few Indian manufacturers of Loxoprofen Sodium Dihydrate.
iii) Experienced promoters and management team driving strategic growth.
iv) High entry barriers due to lengthy customer approval cycles and stringent product quality standards.
v) In-house QC & QA systems ensuring consistent quality and regulatory compliance.
Objects of the Anlon Healthcare Limited IPO:
Anlon Healthcare Limited IPO Details:
Open Date: | Aug 26 2025 |
Close Date: | Aug 29 2025 |
Total Shares: | 1,33,00,000 |
Face Value: | ₹ 10 Per Equity Share |
Issue Type: | Book Building |
Issue Size: | 121.03 Cr. |
Lot Size: | 164 Shares |
Issue Price: | ₹ 86-91 Per Equity Share |
Listing At: | NSE,BSE |
Promoters And Management:
Financials of Anlon Healthcare Limited IPO:
To be updated shortly
Comparison With Peers:
To be updated shortly
Lead Manager of Anlon Healthcare Limited IPO:
Registrar of Anlon Healthcare Limited IPO:
Discussion on Anlon Healthcare Limited IPO:
Leave a Reply
You must be logged in to post a comment.